ATC Group: L03AA Colony stimulating factors

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of L03AA in the ATC hierarchy

Level Code Title
1 L Antineoplastic and immunomodulating agents
2 L03 Immunostimulants
3 L03A Immunostimulants
4 L03AA Colony stimulating factors

Group L03AA contents

Code Title
L03AA02 Filgrastim
L03AA03 Molgramostim
L03AA09 Sargramostim
L03AA10 Lenograstim
L03AA12 Ancestim
L03AA13 Pegfilgrastim
L03AA14
L03AA15
L03AA18
L03AA19

Active ingredients in L03AA

Active Ingredient

Human granulocyte-colony stimulating factor (G-CSF) is a glycoprotein, which regulates the production and release of neutrophils from the bone marrow. Efbemalenograstim alfa is a recombinant fusion protein containing G-CSF, a 16 amino-acid linker, and the Fc portion of human IgG2. Efbemalenograstim alfa is a sustained duration form of G-CSF due to decreased renal clearance. Efbemalenograstim alfa and other G-CSFs have identical modes of action, causing a marked increase in peripheral blood neutrophil counts within 24 hours, with minor increases in monocytes and/or lymphocytes.

Eflapegrastim-xnst is a recombinant human granulocyte growth factor that binds to G-CSF receptors on myeloid progenitor cells and neutrophils, triggering signaling pathways that control cell differentiation, proliferation, migration and survival. Eflapegrastim-xnst has been shown to elevate neutrophil counts in healthy subjects and in cancer patients.

Filgrastim causes marked increases in peripheral blood neutrophil counts within 24 hours, with minor increases in monocytes.

Lenograstim belongs to the cytokine group of biologically active proteins which regulate cell differentiation and cell growth. Lenograstim induces a marked increase in peripheral blood neutrophil counts within 24 hours of administration.

Lipegfilgrastim is a sustained duration form of filgrastim due to decreased renal clearance. Lipegfilgrastim binds to human the G-CSF receptor like filgrastim and pegfilgrastim. Human G-CSF is a glycoprotein that regulates the production and release of functional neutrophils from the bone marrow.

Pegfilgrastim is a sustained duration form of filgrastim due to decreased renal clearance. Pegfilgrastim and filgrastim have been shown to have identical modes of action, causing a marked increase in peripheral blood neutrophil counts within 24 hours, with minor increases in monocytes and/or lymphocytes.

Sargramostim is a recombinant human granulocyte-macrophage colony stimulating factor (rhu GM-CSF) produced by recombinant DNA technology in a yeast (S. cerevisiae) expression system. GM-CSF is a hematopoietic growth factor which induces partially committed progenitor cells to divide and differentiate in the granulocyte-macrophage pathways which include neutrophils, monocytes/macrophages and myeloid-derived dendritic cells.

Related product monographs

Document Type Information Source  
 ACCOFIL Solution for injection / infusion MPI, EU: SmPC European Medicines Agency (EU)
 FULPHILA Solution for injection MPI, EU: SmPC European Medicines Agency (EU)
 GRANOCYTE Powder and solvent for solution for injection/infusion MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 LONQUEX Solution for injection in pre-filled syringe MPI, EU: SmPC European Medicines Agency (EU)
 NEULASTIM Solution for injection MPI, Generic Health Products Regulatory Authority (ZA)
 NEUPOGEN Solution for injection MPI, US: SPL/PLR FDA, National Drug Code (US)
 NIVESTYM Solution for injection MPI, US: SPL/PLR FDA, National Drug Code (US)
 NYVEPRIA Solution for injection MPI, EU: SmPC European Medicines Agency (EU)
 PELMEG Solution for injection MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 RATIOGRASTIM Solution for injection or infusion MPI, EU: SmPC European Medicines Agency (EU)
 ROLVEDON Solution for injection MPI, US: SPL/PLR FDA, National Drug Code (US)
 RYZNEUTA Solution for injection MPI, US: SPL/PLR FDA, National Drug Code (US)
 RYZNEUTA Solution for injection MPI, EU: SmPC European Medicines Agency (EU)
 STIMUFEND Solution for injection MPI, EU: SmPC European Medicines Agency (EU)
 UDENYCA Solution for injection MPI, EU: SmPC European Medicines Agency (EU)
 ZARZIO Solution for injection / infusion MPI, EU: SmPC European Medicines Agency (EU)